Clinical Trials Logo

Recreational Drug Use clinical trials

View clinical trials related to Recreational Drug Use.

Filter by:
  • None
  • Page 1

NCT ID: NCT05571345 Completed - Clinical trials for Recreational Drug Use

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Start date: October 5, 2022
Phase: Phase 1
Study type: Interventional

This will be a randomized, double-blind, placebo- and active-controlled, 5-way crossover study to evaluate the abuse potential, safety and pharmacokinetics of orally administered PF614 relative to oxycodone IR (immediate-release) tablets and placebo.

NCT ID: NCT05567354 Completed - Clinical trials for Recreational Drug Use

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Start date: June 10, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.

NCT ID: NCT05031832 Recruiting - Clinical trials for Recreational Drug Use

Chemsex Engagement and HIV Biomedical Prevention in MSM

Start date: June 1, 2021
Phase:
Study type: Observational

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

NCT ID: NCT03286218 Completed - Clinical trials for Prescription Drug Abuse (Not Dependent)

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

Start date: September 15, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth). This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.